Provectus Biopharmaceuticals Inc (PVCT)
Provectus Biopharmaceuticals Inc. is a clinical-stage biotechnology company listed on OTC Markets under the ticker PVCT. Based in Knoxville, Tennessee, the company focuses on developing immunotherapy medicines for a range of diseases. Its lead compound is rose bengal sodium, a halogenated xanthene, and its pipeline includes PV-10 for stage III and IV melanoma, certain liver cancers, blood cancers, and relapsed or refractory pediatric solid tumors. The company is also developing PH-10 for psoriasis, atopic dermatitis, and skin inflammation, as well as PV-305 for infectious keratitis. Additional programs cover oral and intranasal formulations for infectious and inflammatory conditions, wound healing, tissue regrowth, and selected bacterial and fungal infections. Provectus Biopharmaceuticals was founded in 2002 and adopted its current name in December 2013.
Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Analyst Target Rating | Overall Financial Health | Upcoming Dividend Ex-Date | Dividend Payment Date | Upcoming Dividend | Dividend Yield | Next Earnings Date | P/E Ratio | Price-to-Book Ratio | Price-to-Sales Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Payout Ratio | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
OTC-PVCT
|
$0.047
|
-21.0% Downside
|
Overvalued
|
—
|
—
|
—
|
Weak
|
—
|
—
|
—
|
0.0%
|
August 13, 2026
|
-4.5x
|
-3.7x
|
432.9x
|
25.08 M
|
27.433 M
|
9.9%
|
92.3%
|
-680.7
|
—
|
46.4%
|
